Oncology & Cancer

Multigene testing for all breast cancer patients cost-effective

(HealthDay)—Unselected, multigene testing for all patients with breast cancer would be cost-effective in the United Kingdom and the United States, according to a study published online Oct. 3 in JAMA Oncology.

Medications

Targeted therapy slows progression of advanced prostate cancer

Targeting faulty DNA repair mechanisms in advanced castration resistant prostate cancer can slow progression and potentially improve survival, paving the way for a new approach to treatment of the most common form of cancer ...

Oncology & Cancer

Novel therapy studied for inherited breast cancer

UT Health San Antonio researchers have discovered a novel way to kill cancers that are caused by an inherited mutation in BRCA1, the type of cancer for which actress Angelina Jolie had preventive double mastectomy and reconstructive ...

Oncology & Cancer

Managing ovarian cancer risk in women with BRCA1/2 genetic variants

BRCA1 and BRCA2 genetic variants are a clinically important risk factor for the development of ovarian and breast cancer, and women who carry these variants have a lifetime risk of ovarian cancer of 39%-44% and 11%-17%, respectively.

page 2 from 13